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OBJECTIVES The purpose of this study was to examine the effect of clinical phenotype on the yield of
genetic testing for congenital long QT syndrome (LQTS).
BACKGROUND Since the discovery of the first LQTS susceptibility genes in 1995, numerous genotype-
phenotype relationships have emerged during the past decade of research genetic testing. In
May 2004, LQTS genetic testing became a clinically available molecular diagnostic test.
METHODS Blinded to genetic test results, analysis of the clinical phenotype was performed in 541
consecutive unrelated patients referred to Mayo Clinic’s Sudden Death Genomics Laboratory
for LQTS genetic testing from August 1997 to July 2004.
RESULTS The yield of genetic testing correlated significantly with the corrected QT interval (QTc) and
clinical diagnostic score ranging from 0% when QTc was 400 ms to 62% when QTc was
480 ms (p  0.0001). Among those with the highest clinical probability, the yield was 72%
(89 of 123). The yield fluctuated substantially depending on age at diagnosis in males. Among
physicians who referred 5 patients, the yield ranged from 0% to 80% (p  0.0001).
CONCLUSIONS In this large cohort of unrelated patients referred for LQTS genetic testing, the clinical
phenotype strongly correlated with the likelihood of elucidating a pathogenic mutation with
the cardiac channel gene screen. (J Am Coll Cardiol 2006;47:764–8) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.056American College of Cardiology Foundation
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iffecting 1 in 5,000 persons, long QT syndrome (LQTS) is
he prototypic cardiac channelopathy underscored by pro-
ound genetic and phenotypic heterogeneity (1,2). To date,
ver 400 mutations in five cardiac channel-encoding genes
ave been identified: LQT1 (KCNQ1-encoded potassium
hannel [IKs] mutations), LQT2 (KCNH2-encoded potas-
ium channel [IKr] mutations), LQT3 (SCN5A-encoded
odium channel mutations), and LQT5 and LQT6
KCNE1- or KCNE2-encoded potassium channel beta sub-
nit mutations) (3–6). The LQT4 stems from ankyrin-B
utations and represents the first nonchannel form of
QTS (7).
Over the past decade, genetic testing for LQTS, partic-
larly the three most common genotypes of LQT1 to
QT3, have revealed relatively gene-specific electrocardio-
raphic profiles, responses to epinephrine, arrhythmogenic
riggers and arrhythmogenic temporal states, responsiveness
o beta blockers, treatments, and prognosis (8,9). In May
004, genetic testing for the five LQTS-associated channel
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ccepted September 12, 2005.enotypes became a commercially available clinical diagnos-
ic test in the U.S. (10).
Clinically, genetic testing has been used to risk-stratify
atients, guide treatment decisions, and precisely elucidate
he “carrier” status of potential at-risk relatives (11–14).
aving completed comprehensive mutational analysis in
ne of the largest assembled cohorts of unrelated LQTS
eferrals (6), we scrutinized the effect of clinical phenotype
n the yield of LQTS genetic testing.
ETHODS
tudy population. Between August 1997 and July 2004,
41 consecutive unrelated patients were referred by 103
hysicians to Mayo Clinic’s Sudden Death Genomics Lab-
ratory for LQTS genetic testing in accordance with IRB-
pproved research protocols. Previously, an LQTS-associated
hannel genotype was established in 272 of 541 cases
6,15,16).
Blinded to genotype, clinical phenotype including ethnic-
ty, sex, age at diagnosis, presence or absence of syncope,
eizures, or aborted cardiac arrest, temporally related trig-
ers, family history, and 12-lead electrocardiogram (ECG)
as recorded. A cumulative LQTS diagnostic “Schwartz
nd Moss” score (which is derived in part from the corrected
T interval [QTc], symptoms, and family history) was
ssigned (17). A cumulative score of 4 suggests a robust
henotype and strong probability for LQTS. Sufficient
nformation to derive a clinical score was available in 417 of
41 cases (77%). The QTc data were available for all 417
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as available for 341 cases (63%).
Differences between continuous variables were evaluated
sing unpaired Student t tests, and nominal variables were
nalyzed using chi-square analysis. The chi-square test was
sed for multiple group comparisons. Statistical significance
as considered at p  0.05.
ESULTS
able 1 summarizes the clinical phenotype. Figure 1
etails the distribution of genotypes: LQT1 (n  120),
QT2 (n  93), LQT3 (n  26), LQT5 (n  3), LQT6
n  1), and multiples (n  29). Nearly one-half of the
ohort (269 of 541) had no LQTS-associated channel
utation and are designated “genotype negative.”
The genotype positive subset (n  272) had a signifi-
antly distinct clinical phenotype compared with the geno-
ype negative subset (n  269) in terms of QTc (494  51
s vs. 470  60 ms; p  0.0001) and cumulative LQTS
iagnostic score (Table 1). Forty-one percent of the geno-
ype positive subset had a clinical score of 4 compared
ith 17% of the genotype negative subset (p  0.0001).
here was no difference in sex, ethnicity, age at diagnosis, or
istory of cardiac arrest between the two subsets. Presence
f syncope and family history both trended toward an
ncrease among genotype-positive individuals (46%) com-
ared to genotype-negative individuals (38%, p  0.067).
The yield among white subjects (n  483) was 49%
ompared with 13 of 19 (68%) Hispanics, 8 of 11 blacks
Abbreviations and Acronyms
LQTS  long QT syndrome
QTc  corrected QT interval
Table 1. Demographics of 541 Consecutive Un
Genetic Testing: Comparison of Genotype-Po
Total C
Number of unrelated patients 54
Age at diagnosis (yrs) (range) 24 
(0–
Gender (male/female) 183/
Ethnicity (% white) 9
Average QTc (ms) (range) 482 
(365–
% with QTc 480 ms 4
158/
% with syncope 4
227/
% with cardiac arrest 1
68/
% with positive family history 4
228/
% with “Schwartz and Moss” score 4 2
123/In addition to percentages, absolute numbers for the various clinic
QTc  corrected QT interval.73%), 2 of 3 Asians, 1 of 1 Native American, and 12 of 24
here the ethnicity was not defined. Although the yield was
reater among nonwhites than whites (24 of 34 [71%] vs.
36 of 483 [49%]; p  0.02), ethnicity was not an
ndependent predictor. Rather, the QTc and clinical scores
ere greater among this small subset of nonwhites (data not
hown). Among those with a positive family history of
QTS-attributable symptoms or premature sudden death,
he yield was 55%.
Figure 2 depicts the age and gender distribution with an
verage age at diagnosis of 24  16 years, ranging from 1
ay to 78 years (Table 1). Over two-thirds of the patients
ere under 30 years at diagnosis and males were signifi-
antly younger than females (18  16 years vs. 25  15
ears; p  0.0001). Overall, gender had no effect on the
ield, with 178 of 358 (50%) females and 94 of 183 males
51%) (p  0.28) being genotype positive.
However, the yield fluctuated substantially depending on
ge at diagnosis in males but not in women: 25 of 30 (83%)
ales diagnosed at 5 years of age were genotype positive
ompared with only 13 of 39 (33%) males diagnosed
ed Patients Referred for Long QT Syndrome
and Genotype-Negative Subsets
t
Genotype-
Positive
Genotype-
Negative p Value
272 269 NS
23  16 25  16 NS
(0–75) (0–78)
94/178 89/180 NS
90 96 NS
494  51 470  60 0.0001
(402–700) (365–759)
57 35 0.0001
97/169 61/172 3.3  107
46 38 0.067
126/272 101/269
13 12 NS
36/272 32/269
46 38 0.067
126/272 102/269
41 17 0.0001
89/218 34/199 1  109
igure 1. Summary of long QT syndrome genotypes among 541 consec-
tive unrelated patients.relat
sitive
ohor
1
16
78)
358
3
57
759)
6
341
2
541
2
541
2
541
9
417al parameters are provided as well.
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Yield of LQTS Genetic Testing February 21, 2006:764–8etween 11 and 15 years of age (p  0.0001) (Fig. 3).
uring the first five years of life, the yield was greater in
ales (83%) than in females (53%) (p  0.01). Closer
nspection shows that this difference was due to the yield in
he subset of 28 patients diagnosed during the first year,
herein 11 of 14 (79%) males were genotype positive
ompared to 4 of 14 (29%) females (p  0.02). Unlike
thnicity, age and male gender appear to independently
mpact the yield of genetic testing, because the QTc and
linical scores were similar between males and females at the
arious age categories (data not shown).
The yield correlated significantly with QTc and clinical
“Schwartz and Moss”) score (Fig. 4). The yield ranged
rom 0% for the 7 subjects referred for LQTS genetic
esting despite a resting QTc of 400 ms to 62% for the
44 subjects with a QTc of 480 ms (p  0.0001) (Fig.
A). Among the 417 unrelated cases with an assigned
linical score, an LQTS genotype was established for 43% of
ubjects (93/215) when the clinical score was 4. The yield
as 44% among the 124 patients with insufficient clinical
ata to assign a score. In contrast, among those with the
ighest clinical probability for LQTS (score 4), 89 of 123
72%) were genotype positive: LQT1 (n 39), LQT2 (n
0), LQT3 (n  5), LQT5 (n  1), and multiple (n  14)
p  0.0001) (Fig. 4B).
Finally, we examined the effect of referral source (103
eferring physicians and 91 direct patient self-referrals) on
Figure 2. Age and gender distribution.p
igure 3. Effect of age and gender on yield of long QT syndrome genetic
est.he yield. Among the 18 physicians who referred 5
atients (290 total), the average yield was 51%, which was
o different than the 85 physicians who referred5 patients
49%) or the self-referrals (49%). However, the yield varied
idely among these 18 physicians, ranging from 0% to 80%
p  0.0001). Within our LQTS clinic, there were 22
nrelated patients assigned a clinical score of 4 following
heir comprehensive and systematic assessment by the same
hysician. Subsequently, an LQTS-associated mutation was
lucidated in all 22 (100% yield).
ISCUSSION
urpassed only by the profound genetic heterogeneity that
nderlies LQTS, there is pronounced heterogeneity with
espect to the yield of genetic testing that was impacted
ignificantly and not surprisingly by the robustness of the
linical phenotype. Clearly, the genotype positive patients
ad greater QT intervals and cumulative diagnostic scores
han those without an identifiable cardiac channel mutation.
mong those having the highest clinical probability for
QTS, the yield was 72%.
Given the nonuniformity of clinical assessment by the
early 200 different physicians represented in this study, this
alue (72%) may underestimate the true a priori likelihood
f identifying an LQTS channel genotype in the next
igure 4. Effect of corrected QT interval (QTc) (A) and diagnostic score
B) on yield of genetic test. (A) The yield ranged from 0% when the
ubject’s QTc was 400 ms to 62% when the QTc was 480 ms (p 
.0001). (B) The greatest yield (72%) was achieved among the subset with
cumulative diagnostic score of 4, indicating strong clinical probability
or long QT syndrome.atient strongly suspected to have LQTS. For example, the
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February 21, 2006:764–8 Yield of LQTS Genetic Testingield reached 83% in the subset of males diagnosed with
QTS during the first five years of life. In addition,
ollowing uniform clinical evaluation in our own LQTS
linic, the yield was 100% among those deemed to manifest
robust LQTS phenotype.
Nevertheless, based upon these data, cardiologists can
xpect the current genetic test to capture approximately
hree-fourths of LQTS. Thus, a negative genetic test in an
ndex case with definite LQTS (i.e., genotype negative/
henotype positive LQTS) only informs the physician that
he five channel genotypes have been excluded. Here, a
egative genetic test provides no basis for removing the
iagnosis and means that the physician will struggle with
he correct classification of relatives (12,14).
In stark contrast, a positive genetic test may influence
reatment decisions and will provide the means for precise
carrier” status classification of potentially at-risk relatives.
ith the increased recognition that a significant minority
25% to 50%) of individuals with genetically proven
QTS have a nondiagnostic QTc, the genetic test has
ecome the new gold standard in the identification of
oncealed LQTS (18).
In contrast to its role among those with a definite LQTS
henotype, genetic testing may facilitate a move away from
he diagnosis of LQTS even in light of its known 25% false
egative rate. For example, many patients presently labeled
ith and treated for LQTS received the diagnosis based
pon a clinical phenotype that would only support a
ow/intermediate clinical probability for the diagnosis.
quipped with an objective test (genetic testing) that
ffectively rules out 75% of LQTS, physicians may be more
illing to consider reclassifying such low probability phe-
otype individuals as normal rather than persisting with the
urrent default diagnosis of “borderline” LQTS (12).
Indeed, given the overall yield of 50%, this cohort almost
ertainly contains a spectrum of patients ranging from
ormal individuals with misdiagnosed vasovagal syncope to
QTS phenocopies such as catecholaminergic polymorphic
entricular tachycardia (CPVT) to correctly suspected
QTS. Among patients where there was an ECG for
ndependent review and sufficient information was provided
o assign a clinical score, nearly 60% had a QTc of480 ms
nd over 70% had a clinical score of 4. Without genetic
esting, this phenotypic presentation might translate into a
iagnosis of “probable” or “borderline” LQTS, which typi-
ally results in initiation of medical therapy and restriction
rom competitive sports. Herein, over 40% of such subjects
ould be upgraded from a “probable/borderline” clinical
ssessment to a definitive genetic diagnosis, could be availed
o genotype-guided management, and now have a definitive
iagnostic biomarker available for their family, enabling
recise preclinical presymptomatic classification of all rela-
ives (12).
Undoubtedly, LQTS mimickers or phenocopies reside inhis cohort. Among the subset of 81 patients referred for tenetic testing but known to have a resting QTc of 440
s, the yield of the LQTS genetic test was only 23%,
ndicating that the balance of this subset most likely
epresents nondisease status or perhaps the presence of an
QTS phenocopy such as CPVT (19). Previously, we
emonstrated that 17 of these patients actually have CPVT
20,21). The clinical diagnosis in each patient was “atypical
QTS.” We speculate that the referring physicians consid-
red a clinical diagnosis of concealed LQT1 because of the
ear drowning, drowning, or exertional syncope phenotype
n the setting of a nondiagnostic QTc. Thus, astute recog-
ition of potential LQTS phenocopies such as CPVT and
ndersen-Tawil syndrome (ATS1) will be essential to
irecting the patient’s evaluation toward the proper molec-
lar genetic test. Presently, RyR2 (CPVT1), KCNJ2
ATS1), and ANKB (LQT4) mutation analyses are not
ncluded in the clinical LQTS genetic test (10).
tudy limitations. It is intriguing to conjecture about the
ariable yields derived for the physicians who most used this
esearch test. However, such speculations are made spar-
ngly because of the major limitation associated with this
tudy. In contrast to the rigid uniformity in genotyping this
ohort, the phenotypic data were not procured similarly.
ather, we accepted a sample for genetic testing based solely
pon either physician referral because of a tentative clinical
iagnosis of LQTS or direct patient self-referral because of
physician-rendered diagnosis of LQTS.
Despite the voluntary submission of phenotypic data,
here was excellent cooperation from the majority of refer-
ing physicians and self-referring patients and we were
rovided sufficient clinical and ECG information for the
ajority of cases. Further, the yield (44%) for the subset of
atients with insufficient clinical information mirrored the
ield of the subset whose clinical phenotype was “border-
ine.” With this limitation as a caveat, we suspect that the
eferring physicians with yields 60% were primarily refer-
ing patients with a convincing phenotype for LQTS,
hereas physicians associated with markedly lower yields
ere perhaps using this research test with a “rule-out”
otive in mind. Alternatively, however, the extremely low
ields may suggest that there is ongoing need for continuing
edical education directed toward the proper clinical rec-
gnition of LQTS.
onclusions. This study represents one of the largest series
f consecutive unrelated patients referred for LQTS genetic
esting. The identification of an LQTS channel genotype in
ne-half the cohort has permitted an in-depth analysis of
he clinical parameters exerting the greatest impact on the
ield of such genetic testing. In univariate analyses, ethnic-
ty, age at diagnosis, QTc, “Schwartz and Moss” score, and
eferral source all impacted the yield of the genetic test. The
bservations described should assist in the proper utilization
nd diagnostic interpretation associated with LQTS genetic
esting.
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